Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 1, 2010, Pages 105-110

  Adelman, Ron A ^a   Zheng, Qi ^a   Mayer, Hylton R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BRIMONIDINE; BRINZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; PEGAPTANIB; PREDNISONE; RANIBIZUMAB; TIMOLOL; TIMOLOL MALEATE;

AGED; ANAMNESIS; ARTICLE; CAPSULOTOMY; CASE REPORT; CASE STUDY; COMORBIDITY; DRUG MECHANISM; FEMALE; GONIOSCOPY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MONOTHERAPY; OFF LABEL DRUG USE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PSEUDOPHAKIA; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SLIT LAMP; TEMPORAL ARTERITIS; TONOMETRY; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAOCULAR; INTRAOCULAR PRESSURE; MACULAR DEGENERATION; MALE; OCULAR HYPERTENSION; RETROSPECTIVE STUDIES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 77649324295     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0076     Document Type: Article

References (18)

1. Rosenfeld, P.J., Moshfeghi, A.A., and Puliafito, C.A. Optical coherence tomography fi ndings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg. Lasers Imaging. 36: 331 - 335, 2005.
2. Avery, R.L., Pieramici, D.J., Rabena, M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 113: 363 - 372.e5, 2006.
3. Algvere, P.V., Steén, B., Seregard, S., et al. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol. 86: 482 - 489, 2008.
4. Hollands, H., Wong, J., Bruen, R., et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can. J. Ophthalmol. 42: 807 - 811, 2007.
5. Kim, J.E., Mantravadi, A.V., Hur, E.Y., et al. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am. J. Ophthalmol. 146: 930 - 934.e1, 2008.
6. Mojica, G., Hariprasad, S.M., Jager, R.D., et al. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br. J. Ophthalmol. 92: 584, 2008.
7. Bakri, S.J., Pulido, J.S., McCannel, C.A., et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 23: 181 - 185, 2009.
8. Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355: 1419 - 1431, 2006.
9. Brown, D.M., Kaiser, P.K., Michels, M., et al. ANCHOR Study Group. Ranibizumab versus verteporfi n for neovascular age related macular degeneration. N. Engl. J. Med. 355: 1432 - 1444, 2006.
10. Bakri, S.J., McCannel, C.A., Edwards, A.O., et al. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch. Clin. Exp. Ophthalmol. 246: 955 - 958, 2008.
11. Kahook, M.Y., Kimura, A.E., Wong, L.J., et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg. Lasers Imaging. 40 (3): 293 - 295, 2009.
12. Frenkel, R.E., Mani, L., Toler, A.R., et al. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am. J. Ophthalmol. 143: 1034 - 1035, 2007.
13. Singerman, L.J., Masonson, H., Patel, M., et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br. J. Ophthalmol. 92: 1606 - 1611, 2008.
14. Kotliar, K., Maier, M., Bauer, S., et al. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol. Scand. 85: 777 - 781, 2007.
15. Jahn, C.E., and Emke, M. Long-term elevation of intraocular pressure after neodymium: YAG laser posterior capsulotomy. Ophthalmologica. 210: 85 - 89, 1996.
16. Fourman, S., and Apisson, J. Late-onset elevation in intraocular pressure after neodymium-YAG laser posterior capsulotomy. Arch Ophthalmol. 109: 511 - 513, 1991.
17. Ge, J., Wang, M., Chiang, R., et al. Long-term effect of Nd:YAG laser posterior capsulotomy on intraocular pressure. Arch Ophthalmol. 118: 1334 - 1337, 2000.
18. Kernt, M., Welge-Lüssen, U., Yu, A., et al. Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells [in German]. Ophthalmologe. 104: 965 - 971, 2007.